Nova Laboratories Limited   Report issue

For profit Phase 1 Phase 2
Founded: Wigston United Kingdom (1994)

Organization Overview

First Clinical Trial
2012
NCT01697020
First Marketed Drug
2014
mercaptopurine (purinethol)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Nova Laboratories Limited | Nova Laboratories Sdn Bhd | NOVA LABS LTD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

beta-Thalassemia (Phase 2)

Fatty Liver (Phase 2)

Hemoglobin SC Disease (Phase 2)

Influenza, Human (Phase 1)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 6